Oncology
Conference Coverage
Women with HER2+ metastatic breast cancer are living longer
Overall survival improved 5.6% each year among over 5,000 patients in the study.
Conference Coverage
Panitumumab beats bevacizumab in left-sided mCRC
In the U.S., the choice between an anti-EGFR or anti-VEGF antibody for colorectal cancer has been controversial.
Conference Coverage
International trial finds best regimen for Ewing sarcoma
This is the first randomized head-to-head comparison of chemotherapy regimens in patients with this rare and deadly disease.
From the Journals
Bariatric surgery cuts risk of developing and dying from cancer
“The magnitude of the benefit was very large and dose-dependent.”
Conference Coverage
Mohs surgery in the elderly: The dilemma of when to treat
“The take-home point for me is to treat your whole patient, not just the tumor.”
Conference Coverage
Treating bone loss ups survival for breast cancer patients
Findings suggest a trend toward reduction in contralateral breast cancer in the treatment group.
Conference Coverage
Pembrolizumab before surgery improves survival in early triple negative breast cancer
Treatment shifts residual cancer burden to lower categories.
Conference Coverage
New treatment outperforms chemo in HER2-low breast cancer
The results may cause clinicians to reconsider how they define HER2 expression in breast cancer.
Conference Coverage
New treatment meets unmet need in breast cancer
Expert calls advance incremental, but clinically important for women with HR positive/HER2 negative breast cancer.
Conference Coverage
ctDNA spots breast cancer recurrence
Personalized surveillance technique has the potential to augment adjuvant therapy and improve long-term outcomes.
Conference Coverage
Improved survival in subset of advanced pancreatic cancer
A new drug under study for patients with pancreatic cancer targets EGFR leading to one-year survival rates of 43.6% for patients.